Targeting Intestinal Barrier Function

IMU-856 is a novel, highly innovative, orally available small molecule modulator targeting a protein that serves as a transcriptional regulator of the intestinal barrier function. Immunic has not yet disclosed the target for IMU-856.Based on preclinical data, this compound appears to represent a new and potentially disruptive treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function in patients suffering from diseases like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis and other barrier function associated diseases. Immunic believes that because IMU-856 avoids suppression of the immune functions, it should therefore maintain immune surveillance for patients.

IMU-856 is in preclinical testing. Based on current project timelines, Immunic expects IMU-856 to enter clinical trials in the first half of 2020. In November 2018, Tokyo-based Daiichi Sankyo Co., Ltd. granted Immunic an exclusive global option to exclusively license IMU-856 and related molecules.


Related News

Immunic enters into a global option and license agreement with Daiichi Sankyo